Dual-echo TFE MRI for the assessment of myocardial iron overload in beta-thalassemia major patients

Diagnostic and Interventional Radiology

Volumn 16, Issue 1, 2010, Pages 59-62

  Hazirolan, Tuncay ^a   Eldem, Gonca ^a   Ünal, Şule ^a   Akpinar, Burcu ^a   Gümrük, Fatma ^a   Alibek, Sedat ^b   Haliloǧlu, Mithat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Beta thalassemia; Iron overload; Magnetic resonance imaging; Myocardium

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART MUSCLE; HUMAN; IRON OVERLOAD; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SCHOOL CHILD; TURBO FIELD ECHO MAGNETIC RESONANCE IMAGING;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; FEMALE; HEART DISEASES; HEART SEPTUM; HUMANS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; YOUNG ADULT;

EID: 77749301287     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.4261/1305-3825.DIR.2555-09.1     Document Type: Article

References (24)

1. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331:574-578.
2. Walter PB, Macklin EA, Porter J, et al. Inflammation and oxidant-stress in bthalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica 2008; 93:817-825.
3. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005; 80:70-74.
4. Modell B, Khan M, Darlison M. Survival in beta thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355:2051-2052.
5. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron levels and ventricular function in beta thalassemia. Lancet 2002; 360:516-520.
6. Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med 2001; 111:349-354.
7. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, doubleblind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115:1876-1884.
8. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22:2171-2179.
9. Voskaridou E, Douskou M, Terpos E, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with b thalassemia and sickle cell disease. Br J Haematol 2004; 126:736-742.
10. Westwood M, Anderson LJ, Firmin DN, et al. Interscanner reproducibility of cardiovascular magnetic resonance in the early diagnosis of myocardial iron overload. J Magn Reson Imaging 2003; 18:616-620.
11. Tanner MA, He T, Westwood MA, Firmin DN, Pennell DJ; Thalassemia International Federation Heart T2* Investigators. Multicenter validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 2006; 91:1388-1391.
12. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2006; 8:417-426.
13. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008; 10:12.
14. Li D, Phawale P, Rubin PJ, Haacke EM, Gropler RJ. Myocardial signal response to dipyridamole and dobutamine: demonstrating the BOLD effect using a double echo gradient echo sequence. Magn Reson Med 1996; 36:16-20.
15. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187-1193.
16. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003; 121:187-189.
17. Athanassiou-Metaxa M, Kousi A, Hatzipantelis ES, et al. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients. Haematologica 2004; 89: ELT07.
18. Piga A, Gaglioti C, Fogliaccio E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88:489-496.
19. St Pierre TG, Clark PR, Chua-Anusorn W. Measurement and mapping of liver iron concentrations using magnetic resonance imaging. Ann N Y Acad Sci 2005; 1054:379-385.
20. Ghugre NR, Enriquez CM, Coates TD, Nelson MD Jr, Wood JC. Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging 2006; 23:9-16.
21. Argyropoulou MI, Astrakas L. MRI evaluation of tissue iron burden in patients with ß-thalassemia major. Pediatr Radiol 2007; 37:1191-1200.
22. Stark DD. Hepatic iron overload: paramagnetic pathology. Radiology 1991; 179:333-335.
23. Westwood M, Anderson LJ, Firmin DN, et al. A single breath hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003; 18:33-39.
24. Taigang He, Gatehouse PD, Kirk P, et al. Black blood T2* technique for myocardial iron measurement. J Magn Reson Imaging 2007; 25:1205-1209.